Trial reportCancer immunology, immunotherapy : CII2005
Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma.
Trial report in Cancer immunology, immunotherapy : CII, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma.Cancer immunology, immunotherapy : CII · 2016Pooled it
- Trial
- Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma.Cancer immunology, immunotherapy : CII · 2008Trial
- Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis.Journal of virology · 2008Trial
- The Evolving T Cell Receptor Recognition Code: The Rules Are More Like Guidelines.Immunological reviews · 2025Review
- Adjuvant radiotherapy after salvage surgery for melanoma recurrence in a node field following a previous lymph node dissection.Journal of surgical oncology · 2023Article
- T cell receptor gene repertoire profiles in subgroups of patients with chronic lymphocytic leukemia bearing distinct genomic aberrations.Frontiers in oncology · 2023Article
- Cancer Vaccination against Extracellular Vimentin Efficiently Adjuvanted with Montanide ISA 720/CpG.Cancers · 2022Article
- Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy.Therapeutic advances in vaccines and immunotherapy · 2019Review
- Metastasis review: from bench to bedside.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Review
- Vaccine Potentiation by Combination Adjuvants.Vaccines · 2014Review
- Article
- Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy.Immunogenetics · 2008Article
- Nanotechnology in vaccine delivery.Advanced drug delivery reviews · 2008Review
- Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA.Immunology · 2007Article
- HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination.Cancer immunology, immunotherapy : CII · 2007Article
- Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant.Journal of translational medicine · 2006Article
- IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro.Cancer gene therapy · 2006Article
- A new MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A24 carcinoma cells.Cancer immunology, immunotherapy : CII · 2006Article
- Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer.Cancer immunology, immunotherapy : CII · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies in small groups of patients suggested that immunization of melanoma patients with peptide epitopes recognized by T cells could induce regression of melanoma. This approach was tested in 36 patients with stage IV melanoma. The (MHC class I-restricted) peptides were from gp100, MART-1, tyrosinase, and MAGE-3. The gp100 and MART-1 peptides had been modified to increase their immunogenicity. In half the patients (groups 3 and 4) the peptides were given in the adjuvant Montanide-ISA-720, and half the patients in both groups were given GM-CSF s.c. for 4 days following each injection. Treatment was well tolerated except for two severe erythematous responses to Montanide-ISA-720 and marked inflammatory responses at sites of GM-CSF administration in three patients. There were no objective clinical responses but stabilization of disease for periods from 3 to 12 months were seen in seven patients. Five of these were patients given the peptides in Montanide-ISA-720. Delayed-type hypersensitivity (DTH) skin test responses were also seen mainly in the patients given the peptides in Montanide-ISA-720. GM-CSF did not increase DTH responses in patients in the latter group but may have increased DTH responses in those not given peptides in Montanide-ISA-720. Inflammatory responses around s.c. metastases or regional lymph nodes were observed in two patients. These results suggest that the peptides are more effective when given in the adjuvant Montanide-ISA-720. Nevertheless, results from this study, together with those from a number of comparable studies, indicate that peptide vaccines are currently of minimal benefit to patients and support the need for ongoing development of new strategies in treatment of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.